Antonello Pileggi1, Xiumin Xu, Jianming Tan, Camillo Ricordi. 1. aCell Transplant Center, Diabetes Research Institute bThe DeWitt-Daughtry Family Department of Surgery cDepartment of Microbiology and Immunology, Miller School of Medicine dDepartment of Biomedical Engineering, University of Miami, Miami, Florida, USA eCell and Stem Cell Institute of Xiamen University fFuzhou General Hospital of Xiamen University, Fuzhou, Fujian, China gDepartment of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Abstract
PURPOSE OF REVIEW: Discuss the recent progress on the clinical use of mesenchymal stromal (stem) cells (MSC) in solid organ transplantation (SOT). RECENT FINDINGS: Tissue repair and immunomodulatory properties have been recognized for MSC obtained from different human tissues. MSC-based therapy has been proposed to reduce ischemia-reperfusion injury and to promote immune tolerance. The results of recent clinical trial support the safety and promising effects of autologous and allogeneic MSC in SOT. Collectively, the use of MSC in recipients of living donor kidney transplantation was associated with improved graft function, reduced rejection, ability to omit induction and/or lower maintenance immunosuppression regimen, as well as to treat rejection episodes. SUMMARY: We are living in very exciting times with the implementation of novel clinical trials aimed at establishing safety, feasibility and efficacy of cellular therapies including MSC to improve SOT outcomes. The results of the initial clinical trials support the safety of MSC-based therapy and justifying cautious optimism for the immediate future.
PURPOSE OF REVIEW: Discuss the recent progress on the clinical use of mesenchymal stromal (stem) cells (MSC) in solid organ transplantation (SOT). RECENT FINDINGS: Tissue repair and immunomodulatory properties have been recognized for MSC obtained from different human tissues. MSC-based therapy has been proposed to reduce ischemia-reperfusion injury and to promote immune tolerance. The results of recent clinical trial support the safety and promising effects of autologous and allogeneic MSC in SOT. Collectively, the use of MSC in recipients of living donor kidney transplantation was associated with improved graft function, reduced rejection, ability to omit induction and/or lower maintenance immunosuppression regimen, as well as to treat rejection episodes. SUMMARY: We are living in very exciting times with the implementation of novel clinical trials aimed at establishing safety, feasibility and efficacy of cellular therapies including MSC to improve SOT outcomes. The results of the initial clinical trials support the safety of MSC-based therapy and justifying cautious optimism for the immediate future.
Authors: Marlies E J Reinders; Johan W de Fijter; Helene Roelofs; Ingeborg M Bajema; Dorottya K de Vries; Alexander F Schaapherder; Frans H J Claas; Paula P M C van Miert; Dave L Roelen; Cees van Kooten; Willem E Fibbe; Ton J Rabelink Journal: Stem Cells Transl Med Date: 2013-01-24 Impact factor: 6.940
Authors: Tatsuo Kawai; A Benedict Cosimi; Thomas R Spitzer; Nina Tolkoff-Rubin; Manikkam Suthanthiran; Susan L Saidman; Juanita Shaffer; Frederic I Preffer; Ruchuang Ding; Vijay Sharma; Jay A Fishman; Bimalangshu Dey; Dicken S C Ko; Martin Hertl; Nelson B Goes; Waichi Wong; Winfred W Williams; Robert B Colvin; Megan Sykes; David H Sachs Journal: N Engl J Med Date: 2008-01-24 Impact factor: 91.245
Authors: Philippe Bourin; Bruce A Bunnell; Louis Casteilla; Massimo Dominici; Adam J Katz; Keith L March; Heinz Redl; J Peter Rubin; Kotaro Yoshimura; Jeffrey M Gimble Journal: Cytotherapy Date: 2013-04-06 Impact factor: 5.414
Authors: Bo Wang; Kevin Yao; Brooke M Huuskes; Hsin-Hui Shen; Junli Zhuang; Catherine Godson; Eoin P Brennan; Jennifer L Wilkinson-Berka; Andrea F Wise; Sharon D Ricardo Journal: Mol Ther Date: 2016-05-18 Impact factor: 11.454
Authors: Andrew J Glowacki; Riccardo Gottardi; Sayuri Yoshizawa; Franco Cavalla; Gustavo P Garlet; Charles Sfeir; Steven R Little Journal: Ann Biomed Eng Date: 2014-09-23 Impact factor: 3.934